Extended RAS analysis and subsequent anti-EGFR and anti-VEGF treatment (tx) in PEAK: A first-line phase 2 study of FOLFOX6 + panitumumab (pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC).

Authors

Fernando Rivera

Hospital Universitario Marqués de Valdecilla, Santander, Spain

Fernando Rivera , Lee Steven Schwartzberg , Meinolf Karthaus , Gianpiero Fasola , Jean-Luc Canon , J. Randolph Hecht , Ying Tian , Hua Yu , Kelly Smith Oliner , William Y. Go

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild‑type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC).

First Author: Lee Steven Schwartzberg

insert_chart_outlined

Poster

2018 Gastrointestinal Cancers Symposium

bookmark_border

Analysis of RAS/BRAF mutations in a randomized phase II WJOG6510G study of panitumumab plus irinotecan versus cetuximab plus irinotecan in chemorefractory metastatic colorectal cancer.

First Author: Tomohiro Nishina

insert_chart_outlined

Poster

2018 Gastrointestinal Cancers Symposium

bookmark_border

Impact of primary tumor side (TS) on outcomes of once-every-2-weeks (q2w) cetuximab + first-line (1L) FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.

First Author: Timothy Jay Price

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

A randomized multicenter phase II study of FOLFIRI plus either panitumumab (Pmab) or bevacizumab (Bmab) as second-line treatment for wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) with exploratory biomarker analysis by liquid biopsy: WJOG6210G.

First Author: Kohei Shitara